Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV gag protein-induced t cell responses in nonhuman primates

Journal of Immunology

Volumn 190, Issue 8, 2013, Pages 4103-4115

  Park, Haesun ^a   Adamson, Lauren ^a   Ha, Tae ^a   Mullen, Karl ^a   Hagen, Shoko I ^a   Nogueron, Arys ^a   Sylwester, Andrew W ^a   Axthelm, Michael K ^a   Legasse, Al ^a   Piatak, Michael ^b   Lifson, Jeffrey D ^c   McElrath, Juliana M ^d   Picker, Louis J ^a   Seder, Robert A ^e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b SAIC FREDERICK INC   (United States)

^c Nanobiology Program   (United States)

^d USA   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CPG OLIGODEOXYNUCLEOTIDE; GAG PROTEIN VACCINE; MONTANIDE ISA 51; PEPTIDE VACCINE; PHOSPHORYL LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN CELL; IMMUNIZATION; LUNG LAVAGE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TH1 CELL; VIRUS INHIBITION; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 84876001825     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202958     Document Type: Article

References (53)

1. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al; MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220.
2. Barouch, D. H., J. Liu, H. Li, L. F. Maxfield, P. Abbink, D. M. Lynch, M. J. Iampietro, A. SanMiguel, M. S. Seaman, G. Ferrari, et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93.
3. Hansen, S. G., J. C. Ford, M. S. Lewis, A. B. Ventura, C. M. Hughes, L. Coyne-Johnson, N. Whizin, K. Oswald, R. Shoemaker, T. Swanson, et al. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
4. Lakhashe, S. K., V. Velu, G. Sciaranghella, N. B. Siddappa, J. M. Dipasquale, G. Hemashettar, J. K. Yoon, R. A. Rasmussen, F. Yang, S. J. Lee, et al. 2011. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 29: 5611-5622.
5. Lu, S. 2009. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21: 346-351.
6. Loré, K., and G. B. Karlsson Hedestam. 2009. Novel adjuvants for B cell immune responses. Curr Opin HIV AIDS 4: 441-446.
7. Coffman, R. L., A. Sher, and R. A. Seder. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
8. Foged, C. 2011. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther. Deliv. 2: 1057-1077.
9. Leroux-Roels, G. 2010. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28(Suppl 3): C25-C36.
10. Duthie, M. S., H. P. Windish, C. B. Fox, and S. G. Reed. 2011. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239: 178-196.
11. Luke, J. M., G. G. Simon, J. Söderholm, J. S. Errett, J. T. August, M. Gale, Jr., C. P. Hodgson, and J. A. Williams. 2011. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J. Virol. 85: 1370-1383.
12. Le Bon, A., and D. F. Tough. 2008. Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev. 19: 33-40.
13. Kastenmüller, K., U. Wille-Reece, R. W. Lindsay, L. R. Trager, P. A. Darrah, B. J. Flynn, M. R. Becker, M. C. Udey, B. E. Clausen, B. Z. Igyarto, et al. 2011. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest. 121: 1782-1796.
14. Keppler, S. J., K. Rosenits, T. Koegl, S. Vucikuja, and P. Aichele. 2012. Signal 3 cytokines as modulators of primary immune responses during infections: the interplay of type I IFN and IL-12 in CD8 T cell responses. PLoS ONE 7: e40865.
15. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6: 769-776.
16. Kasturi, S. P., I. Skountzou, R. A. Albrecht, D. Koutsonanos, T. Hua, H. I. Nakaya, R. Ravindran, S. Stewart, M. Alam, M. Kwissa, et al. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543-547.
17. Wille-Reece, U., B. J. Flynn, K. Loré, R. A. Koup, A. P. Miles, A. Saul, R. M. Kedl, J. J. Mattapallil, W. R. Weiss, M. Roederer, and R. A. Seder. 2006. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203: 1249-1258.
18. Flynn, B. J., K. Kastenmüller, U. Wille-Reece, G. D. Tomaras, M. Alam, R. W. Lindsay, A. M. Salazar, B. Perdiguero, C. E. Gomez, R. Wagner, et al. 2011. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc. Natl. Acad. Sci. USA 108: 7131-7136.
19. Sundling, C., S. O'Dell, I. Douagi, M. N. Forsell, A. Mörner, K. Loré, J. R. Mascola, R. T. Wyatt, and G. B. Karlsson Hedestam. 2010. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus. J. Virol. 84: 9086-9095.
20. Lumsden, J. M., S. Nurmukhambetova, J. H. Klein, J. Sattabongkot, J. W. Bennett, S. Bertholet, C. B. Fox, S. G. Reed, C. F. Ockenhouse, R. F. Howard, et al. 2012. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine 30: 3311-3319.
21. Loré, K., M. R. Betts, J. M. Brenchley, J. Kuruppu, S. Khojasteh, S. Perfetto, M. Roederer, R. A. Seder, and R. A. Koup. 2003. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol. 171: 4320-4328.
22. Ito, T., H. Kanzler, O. Duramad, W. Cao, and Y. J. Liu. 2006. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 107: 2423-2431.
23. Ito, T., R. Amakawa, T. Kaisho, H. Hemmi, K. Tajima, K. Uehira, Y. Ozaki, H. Tomizawa, S. Akira, and S. Fukuhara. 2002. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. 195: 1507-1512.
24. Aoki, K., C. Barker, X. Danthinne, M. J. Imperiale, and G. J. Nabel. 1999. Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro. Mol. Med. 5: 224-231.
25. Asmal, M., Y. Sun, S. Lane, W. Yeh, S. D. Schmidt, J. R. Mascola, and N. L. Letvin. 2011. Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. J. Virol. 85: 5465-5475.
26. Walker, J. M., H. T. Maecker, V. C. Maino, and L. J. Picker. 2004. Multicolor flow cytometric analysis in SIV-infected rhesus macaque. Methods Cell Biol. 75: 535-557.
27. Cline, A. N., J. W. Bess, M. Piatak, Jr., and J. D. Lifson. 2005. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34: 303-312.
28. Abbink, P., A. A. Lemckert, B. A. Ewald, D. M. Lynch, M. Denholtz, S. Smits, L. Holterman, I. Damen, R. Vogels, A. R. Thorner, et al. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81: 4654-4663.
29. *01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J. Immunol. 160: 6062-6071.
30. Bennekov, T., J. Dietrich, I. Rosenkrands, A. Stryhn, T. M. Doherty, and P. Andersen. 2006. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Myco-bacterium tuberculosis. Eur. J. Immunol. 36: 3346-3355.
31. Giraldo-Vela, J. P., A. T. Bean, R. Rudersdorf, L. T. Wallace, J. T. Loffredo, P. Erickson, N. A. Wilson, and D. I. Watkins. 2010. Simian immunodeficiency virus-specific CD4+ T cells from successful vaccinees target the SIV Gag capsid. Immunogenetics 62: 701-707.
32. *08-positive macaques. J. Virol. 83: 11514-11527.
33. Sacha, J. B., M. R. Reynolds, M. B. Buechler, C. Chung, A. K. Jonas, L. T. Wallace, A. M. Weiler, W. Lee, S. M. Piaskowski, T. Soma, et al. 2008. Differential antigen presentation kinetics of CD8+ T-cell epitopes derived from the same viral protein. J. Virol. 82: 9293-9298.
34. Liu, J., K. L. O'Brien, D. M. Lynch, N. L. Simmons, A. La Porte, A. M. Riggs, P. Abbink, R. T. Coffey, L. E. Grandpre, M. S. Seaman, et al. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91.
35. Levitz, S. M., and D. T. Golenbock. 2012. Beyond empiricism: informing vaccine development through innate immunity research. Cell 148: 1284-1292.
36. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529.
37. Stahl-Hennig, C., M. Eisenblätter, E. Jasny, T. Rzehak, K. Tenner-Racz, C. Trumpfheller, A. M. Salazar, K. Uberla, K. Nieto, J. Kleinschmidt, et al. 2009. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog. 5: e1000373.
38. Tewari, K., B. J. Flynn, S. B. Boscardin, K. Kastenmueller, A. M. Salazar, C. A. Anderson, V. Soundarapandian, A. Ahumada, T. Keler, S. L. Hoffman, et al. 2010. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and aDEC-CSP in non human primates. Vaccine 28: 7256-7266.
39. Wille-Reece, U., B. J. Flynn, K. Loré, R. A. Koup, R. M. Kedl, J. J. Mattapallil, W. R. Weiss, M. Roederer, and R. A. Seder. 2005. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. USA 102: 15190-15194.
40. Lindenstrøm, T., E. M. Agger, K. S. Korsholm, P. A. Darrah, C. Aagaard, R. A. Seder, I. Rosenkrands, and P. Andersen. 2009. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182: 8047-8055.
41. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850.
42. Longhi, M. P., C. Trumpfheller, J. Idoyaga, M. Caskey, I. Matos, C. Kluger, A. M. Salazar, M. Colonna, and R. M. Steinman. 2009. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206: 1589-1602.
43. Goulder, P. J., and D. I. Watkins. 2008. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8: 619-630.
44. Maurer, T., A. Heit, H. Hochrein, F. Ampenberger, M. O'Keeffe, S. Bauer, G. B. Lipford, R. M. Vabulas, and H. Wagner. 2002. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur. J. Immunol. 32: 2356-2364.
45. Oh, J. Z., and R. M. Kedl. 2010. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J. Immunol. 185: 4602-4608.
46. Wagner, H. 2009. The immunogenicity of CpG-antigen conjugates. Adv. Drug Deliv. Rev. 61: 243-247.
47. Picker, L. J., S. G. Hansen, and J. D. Lifson. 2012. New paradigms for HIV/AIDS vaccine development. Annu. Rev. Med. 63: 95-111.
48. Staprans, S. I., A. P. Barry, G. Silvestri, J. T. Safrit, N. Kozyr, B. Sumpter, H. Nguyen, H. McClure, D. Montefiori, J. I. Cohen, and M. B. Feinberg. 2004. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc. Natl. Acad. Sci. USA 101: 13026-13031.
49. Brown, D. M. 2010. Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy. Cell. Immunol. 262: 89-95.
50. Soghoian, D. Z., H. Jessen, M. Flanders, K. Sierra-Davidson, S. Cutler, T. Pertel, S. Ranasinghe, M. Lindqvist, I. Davis, K. Lane, J. Rychert, E. S. Rosenberg, A. Piechocka-Trocha, A. L. Brass, J. M. Brenchley, B. D. Walker, and H. Streeck 2012. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci. Transl. Med. 4: 123ra125.
51. Sacha, J. B., J. P. Giraldo-Vela, M. B. Buechler, M. A. Martins, N. J. Maness, C. Chung, L. T. Wallace, E. J. León, T. C. Friedrich, N. A. Wilson, et al. 2009. Gag-and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc. Natl. Acad. Sci. USA 106: 9791-9796.
52. Le Bon, A., G. Schiavoni, G. D'Agostino, I. Gresser, F. Belardelli, and D. F. Tough. 2001. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470.
53. Le Bon, A., V. Durand, E. Kamphuis, C. Thompson, S. Bulfone-Paus, C. Rossmann, U. Kalinke, and D. F. Tough. 2006. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J. Immunol. 176: 4682-4689.